Screening of natural molecules for their neuromodulatory potential through in-vitro and in-vivo models

Abstract

Alzheimer’s disease (AD) is now been considered to be the sixth leading cause of death in the US. AD is now been referred to as “Type III Diabetes” due to reported glucose metabolism dysfunction. A number of preclinical studies indicate the inverse relation between the level of insulin and the AD pathology. With an increase in the level of insulin, decrease in the pathogenesis of AD has been observed. Alzheimer’s disease (AD) is a chronic neurodegenerative disorder of the central nervous system associated with progressive cognitive and memory loss. AD accounts for around 50-60% of dementia cases and is thus considered to be the most common cause of age-related. It is more common in women [Bassil et. al., 2012]. Apart from age, lifestyle and genetics also considered to be risk factors [National Institutes of Health, 2016]. Type 2 diabetes mellitus (T2D) is yet another factor that greatly enhances the risk of developing this disorder by 50-60% [Chami et. al., 2016; Mittal &Katare, 2016].